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ABSTRACT
Background: Equations to predict maximum heart rate (HRmax) in heart failure (HF) patients receiving
b-adrenergic blocking (BB) agents do not consider the cause of HF. We determined equations to predict
HRmax in patients with ischemic and nonischemic HF receiving BB therapy.
Methods and Results: Using treadmill cardiopulmonary exercise testing, we studied HF patients receiving
BB therapy being considered for transplantation from 1999 to 2010. Exclusions were pacemaker and/or im-
plantable defibrillator, left ventricle ejection fraction (LVEF)O50%, peak respiratory exchange ratio (RER)
!1.00, and Chagas disease. We used linear regression equations to predict HRmax based on age in ischemic
and nonischemic patients. We analyzed 278 patients, aged 47 6 10 years, with ischemic (n 5 75) and
nonischemic (n 5 203) HF. LVEF was 30.8 6 9.4% and 28.6 6 8.2% (P 5 .04), peak VO2 16.9 6 4.7
and 16.9 6 5.2 mL kg1 min1 (P 5 NS), and the HRmax 130.8 6 23.3 and 125.3 6 25.3 beats/min
(P 5 .051) in ischemic and nonischemic patients, respectively. We devised the equation HRmax 5 168 
0.76  age (R2 5 0.095; P 5 .007) for ischemic HF patients, but there was no significant relationship be-
tween age and HRmax in nonischemic HF patients (R
2 5 0.006; P 5 NS).
Conclusions: Our study suggests that equations to estimate HRmax should consider the cause of HF. (J Car-
diac Fail 2012;18:831e836)
Key Words: Heart rate, exercise testing, heart failure, b-adrenergic receptor blocker.
Heart failure (HF) is a complex clinical syndrome asso-
ciated with high rates of morbidity and mortality.1 b-Adren-
ergic receptor blocking (BB) agents have been widely used
in this condition since it was proven that they improve sur-
vival and clinical status and reduce hospitalization.2e6
The main clinical manifestation in these patients is ex-
ercise intolerance, and cardiopulmonary exercise testing
(CPET) is a useful tool in prognostic evaluation, provid-
ing essential information when patients are considered
for cardiac transplantation. In this setting, they must be
evaluated with optimized clinical therapy, including BB
agents.
Heart rate (HR) response is one of the parameters pro-
vided by CPET, and chronotropic incompetence (CI) has
been commonly defined by incapacity to reach an arbitrary
percentage of the predicted maximum HR (HRmax). CI has
been recognized as an independent prognostic marker in
patients with7 and without8e10 HF taking11 or not taking8
BB agents. However, the determination of predicted HRmax
is usually based on the equation 220  age,10 which is not
appropriate for patients taking BB agents.12 Furthermore,
the reported prevalence of CI in HF patients is highly vari-
able and may reflect different criteria used to define CI as
well as differences in patient characteristics.10 Recently,
an equation that predicts HRmax based on age, resting
HR, and ergometer type was determined for patients with
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HF.13 However, it did not consider the impact of the cause
of HF on HRmax.
The purpose of the present study was to determine an
equation to predict HRmax in patients with ischemic and
nonischemic HF who are receiving BB therapy.
Methods
Population and Study Design
A retrospective analysis was performed in 655 consecutive pa-
tients with HF referred for heart transplantation from 1999 to
2010. All patients underwent CPET; they had been clinically stable
before CPET. Excluded from the analysis were 377 patients because
they were either participating in regular physical activity $30 min-
utes 3 times a week (n5 45), were!20 years old (n5 25), had no
optimized drug therapy (n 5 10), had incomplete data (n 5 4) or
interrupted test owing to hemodynamic or electrocardiographic
complications (n 5 50), or had respiratory limitations (n 5 10),
left ventricular ejection fraction (LVEF) $50% (n 5 30), atrial fi-
brillation (n5 20), pacemaker or implantable defibrillator (n5 37),
peak respiratory exchange ratio (RER)!1.00 (n5 120), or Chagas
disease (n 5 26). The final sample included 278 patients aged
20e76 years with systolic HF (SHF), receiving a stable dose of
a BB for O3 months before the CPET. All patients were taking
BBs (carvedilol 80%, bisoprolol 15%, and metoprolol 5%) at the
maximum tolerated dose at the discretion of the treating physician.
Furthermore, 80% of the patients were taking angiotensin-
converting enzyme inhibitor (ACE-I), 21% angiotensin receptor an-
tagonist (ARA), and 58% spironolactone. We asked them to take
their medications normally, including on the day of the test.
LVEF and clinical data were obtained from the last echocardiogram
and the patient’s medical record, respectively.
Ischemic HF was defined as SHF with past myocardial infarc-
tion or revascularization (surgical or percutaneous). The patients
were enrolled in 6 age-range groups (years): 20e29, 30e39,
40e49, 50e59, 60e69, and $70.
The study was approved by the Institutional Review Board of
the Ethics Committee, and it was in accordance with the Declara-
tion of Helsinki.
Exercise Testing
All referred patients underwent maximum exercise testing using
a modified Naughton protocol and a metabolic cart. CPET was
carried out on a programmable treadmill (TMX425 Stress Tread-
mill; TrackMaster, Newton, Kansas, USA) in a controlled-
temperature room (21e23C) with monitoring of cardiac rhythm
(CardioSoft 6.5; GE Medical Systems IT, Milwaukee, Wisconsin,
USA) and blood pressure (Tango Stress BP; SunTech Medical,
Morrisville, North Carolina, USA) as previously described.14
The 12-lead electrocardiogram and HR were monitored with the
patient in the standing position before and throughout the exercise
period and during recovery. Ventilation (VE), oxygen uptake (VO2),
and carbon dioxide output (VCO2) were measured breath by breath
with the use of a computerized system (Vmax Encore 29; Sensor-
Medics Corp, Yorba Linda, California, USA). The RER had been
recorded at each average sample obtained during each stage of
the protocol. The highest VO2 and HR levels (1-minute mean) at
the end of exercise were considered to be the peak VO2 and HRmax,
respectively. The VE-VCO2 slope was calculated by automatic lin-
ear regression fitting with the breath-by-breath values obtained
throughout the whole exercise. Patients were instructed and encour-
aged to exercise to their maximum capacity.
The predicted peak VO2 was calculated according to normative
values for age, sex, and body weight from Wasserman et al.15 The
percentage of predicted peak VO2 was determined by dividing the
weight-normalized peak VO2 by the predicted peak VO2 and then
multiplying by 100. Predicted HRmax was determined by the equa-
tion HRmax 5 164  0.7  age, which was validated for patients
receiving BB therapy.12 Reserve HR was the absolute difference
between HRmax and resting HR (HRrest).
We also calculated the values of predicted HRmax in our sample
by the equation HRmax 5 119 þ 0.5(HRrest)  0.5(age), which we
called ‘‘HF-pred HR.’’13
Statistical Analysis
All data are reported as mean 6 SD, and the statistical program
SPSS 13.0 for Windows (SPSS, Chicago, Illinois, USA) was used
to perform the statistical analysis. The Kolmogorov-Smirnov test
was applied to ensure a gaussian distribution of the results. One-
way analysis of variance (ANOVA) was used to analyze differ-
ences in the subjects’ characteristics at baseline. Bonferroni post
hoc analysis was used to determine the significance of the data
that was indicated by 1-way ANOVA. Pearson correlation was
used to assess the relationship between age and HRmax. Linear re-
gression was used to generate the equation to predict HRmax from
age for ischemic and nonischemic HF patients receiving BB ther-
apy. The significance level was set at P ! .05. Bootstraping re-
sampling based on 1,000 bootstrap samples was used for
validation in each HF group (ischemic and nonischemic).
Results
Population and Study Design
The clinical baseline characteristics of the whole sample
and according to the cause of HF are listed in Table 1. Most
patients were male and had nonischemic HF. We observed
that LVEF was lower for nonischemic than for ischemic
patients.
Table 2 presents the results of linear regression model for
HRmax in ischemic and nonischemic HF patients. We found
that age is a significant but weak predictor of HRmax in is-
chemic patients only (R25 0.095; P5 .007) and derived an
equation HRmax 5 168  0.77  age. On the other hand,
Table 1. Clinical Baseline Characteristics and Comparison
Between Ischemic and Nonischemic Heart Failure Patients
Parameter
Total
(n 5 278)
Ischemic
(n 5 75)
Nonischemic
(n 5 203)
P
Value
Male, n (%) 207 (75) 59 (79) 148 (73) NS
Age, y 47.2 6 10.3 48.9 6 9.3 46.6 6 10.6 NS
Weight, kg 70.5 6 16.0 70.2 6 16.3 70.6 6 16.0 NS
Height, cm 164 6 10 164 6 11 164 6 9 NS
BMI, kg/m2 25.8 6 5.3 25.2 6 5.9 26.1 6 5.1 NS
NYHA functional
class
2.2 6 0.9 2.3 6 0.9 2.2 6 0.9 NS
LVEF, % 29.2 6 8.6 30.8 6 9.4 28.6 6 8.2 .04
Hemoglobin, g/dL 13.6 6 1.6 13.3 6 1.9 13.6 6 1.6 NS
BMI, body mass index; NYHA, New York Heart Association; LVEF, left
ventricle ejection fraction.
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there was no significant relationship between age and
HRmax in nonischemic HF patients (R
2 5 0.006; P 5 NS).
The bootstrap resampling analysis showed bias 0.004, stan-
dard error 0.292, 95% CI 1.333 to 0.170, and P 5
.011 for ischemic and bias 0.005, standard error 0.176,
95% CI 0.531 to 0.179, and P 5 .296 for nonischemic
HF patients.
Table 3 presents the exercise parameters and a compari-
son between ischemic and nonischemic HF patients. We
found that nonischemic patients had a higher VE-VCO2
slope. The absolute HRmax tended to be lower and the per-
centage of predicted HRmax was significantly lower for non-
ischemic patients, using the validated equations both for
patients receiving BBs and for HF patients (HF-pred HR)
to predict HRmax. We did not find any difference in peak
RER, peak VO2 (mL kg
1 min1), peak VO2 (% of pre-
dicted), or reserve HR between ischemic and nonischemic
patients.
We compared HRmax between ischemic and nonischemic
HF patients in each age group, as presented in Table 4. The
20e29-year and $70-year groups were excluded because
they included only nonischemic patients. We found that
HRmax was significantly higher in ischemic than in noni-
schemic patients in the age groups 30e39 and 40e49 years,
but there was no difference in the age groups 50e59 and
60e69 years. Reserve HR, HRrest, and peak VO2 were
not different according to etiology in any group. Interest-
ingly, the VE-VCO2 slope was significantly higher and
LVEF significantly lower in nonischemic HF patients
only in the 40e49 group. Considering only nonischemic
patients, we did not find a significant difference in any of
these parameters among age groups. On the other hand,
for ischemic patients, we found that HRmax was signifi-
cantly lower in the 50e59-year than in the 30e39-year
group, and peak VO2 was lower in the 60e69-year and
LVEF lower in the 50e59-year compared with the
40e49-year group.
Discussion
We have found that age-related predicted HRmax obtained
by linear regression is different between ischemic and non-
ischemic HF patients. There is only a weak relationship be-
tween HRmax and age in ischemic patients, and age is not
a significant predictor of HRmax in nonischemic patients.
To our knowledge, this is the first study to demonstrate a dif-
ference between ischemic and nonischemic HF patients.
The equation 220  age is a common equation used to de-
termine the predicted HRmax, and it has been applied to cal-
culate indices that have prognostic value in HF patients.
However, earlier studies12,16 indicated that this equation
should not be used in patients using BB agents. Brawner
et al12 developed and validated an equation to predict HRmax
in patients using BB agents: HRmax 5 164  0.72  age.
They included patients with coronary artery disease and ex-
cluded those with HF or LVEF !50%. Interestingly, that
equation is very similar to what we found for ischemic pa-
tients, suggesting that it could apply to individuals with
coronary artery disease using BB agents regardless of ven-
tricular function. Recently, Keteyian et al13 validated a sim-
plified equation based on age, HRrest, and ergometer
[HRmax5 119 þ 0.5  (resting HRrest)  0.5(age) for tread-
mill] in HF patients taking BB agents, of which 49% were
ischemic.
Table 2. Linear Regression Model for Maximum Heart
Rate in Ischemic and Nonischemic Heart Failure Patients
Variable b SE P Value R2 SEE
Ischemic
Constant 168.347 13.808
Age 0.768 0.278 .007* 0.095 22
Nonischemic
Constant 133.929 8.014
Age 0.184 0.168 NS* .006 25
SE, standard error; SEE, standard error of the estimate.
*t test.
Table 3. Exercise Parameters and Comparison Between Ischemic and Nonischemic Heart Failure Patients
Parameter Total Ischemic Nonischemic P Value
HRrest, bpm 77.6 6 15.3 79.6 6 16.2 76.8 6 15.0 NS
Equation HRmax 168.3  0.77  age 133.9  0.18  age d
HRmax, bpm 126.8 6 24.9 130.8 6 23.3 125.3 6 25.3 .051
Reserve HR 48.7 6 20.8 50.9 6 19.2 47.9 6 21.3 NS
% HRmax* 97.0 6 19.2 100.7 6 17.0 95.6 6 19.8 .02
% HRmax (HF-pred HR)
y 94.0 6 16.1 96.9 6 14.1 92.9 6 16.6 .02
% HRmax (proposed equation)
z 99.8 6 19.3 99.7 6 16.8 99.9 6 20.1 NS
Peak RER 1.08 6 0.07 1.07 6 0.06 1.08 6 0.08 NS
Peak VO2, mL kg
1 min1 16.9 6 5.1 16.9 6 4.7 16.9 6 5.2 NS
Peak VO2 (% max pred) 46.0 6 11.9 46.1 6 11.4 46.0 6 12.0 NS
VE-VCO2 slope 35.0 6 10.0 32.7 6 9.5 35.7 6 10.1 .01
LVEF, left ventricle ejection fraction; HR, heart rate; bpm, beats per minute; HRmax, maximum heart rate; HRrest, resting heart rate; % HRmax, percentage
of predicted HRmax using equation 164  0.7  age; RER, respiratory exchange ratio; VO2, oxygen uptake.
*HRmax was calculated by the equation 164  0.7  age.12yHRmax was calculated by the equation 119 þ (0.5  HRrest)  (0.5  age).13zHRmax was calculated by the derived equations proposed in this study: 168.3  0.77  age for ischemic and 133.9  0.18  age for nonischemic HF
patients.
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However, both of those equations had a considerable in-
dividual variation, with a standard error of the estimate
(SEE) of 18 beats/min. Many factors may have contributed
to that, such as prior acute myocardial infarction, although
it did not explain most of the variation in the present study.
We have found that these equations seem to overestimate
HRmax in nonischemic HF patients and that age did not in-
fluence HRmax, because the slope of the linear regression is
not different from zero. Considering only ischemic HF pa-
tients, we have also found high individual variation (SEE
22) and weak relationship between age and HRmax, indicat-
ing that other factors may have influenced this variation,
such as severity of the disease and individual tolerability
to BB therapy.
We have found no significant difference in either reserve
or resting HR according to etiology among age groups. The
small number of patients in each group may have limited
these results. In earlier studies, reserve HR was not a signif-
icant prognostic marker in patients receiving BBs.7 In addi-
tion, in HF patients not receiving BBs, it was shown that
even though it is a predictor of mortality in univariate anal-
ysis, reserve HR loses its prognostic value in multivariate
analysis.7,17 Although blunted HR response induced by
BB agents may be responsible for its lack of prognostic
value, we demonstrated that HRmax is influenced by age
in different ways according to the cause of the heart failure.
The reasons for these differences are uncertain. Patients
with HF have abnormal sympathetic function in the myo-
cardium, characterized by a reduction in presynaptic nor-
epinephrine (NE) uptake and postsynaptic b-adrenoceptor
density.18 Altered expression of b-adrenoceptor density
was demonstrated in both ischemic and nonischemic HF
patients.19,20 It has been considered that down-regulation
of b-adrenoceptor could be due to a locally increased NE
concentration in the synaptic cleft.18
Metaiodobenzylguanidine (MIBG) is an NE analog and,
likewise, is captured in the presynaptic membrane.21e23 Its
neuronal uptake reflects the distribution and integrity of the
heart’s sympathetic innervation.24 Earlier studies have ana-
lyzed the prognostic value of cardiac scintigraphy with the
use of MIBG labeled with iodine-123 (123I-MIBG) in HF
patients.24e30 It has been found that decreased 123I-MIBG
uptake and increased washout rate are independent predic-
tors of mortality in patients with HF independently from
etiology.18,31e33 On the other hand, clinical treatment in-
cluding ACE-I,34 ARA,35 BBs,36,37 and spironolactone38
can improve sympathetic neuronal uptake function and
could affect HR exercise response. Chizzola et al39 found
a 14% increase in MIBG uptake after 2 months of treatment
with carvedilol. This indicates an improved neuronal reup-
take of NE with carvedilol, preventing the down-regulation
of expression of adrenergic receptors (reverse remodeling
of the cardiac sympathetic nervous system). Whether
a higher increase occurs in b-adrenoceptor activity after
chronic treatment with BB agents for ischemic versus non-
ischemic patients is still uncertain. Recently, Rocha Mes-
sias et al40 found that a group of HF patients taking BBs
with an altered washout rate ($27%) had a peak HR signif-
icantly lower than patients with a normal washout rate. De-
spite the small sample, that study suggests that lower peak
HR is, at least in part, associated with accelerated sympa-
thetic tone or NE spillover, leading to a down-regulation
of b-adrenoceptors. Interestingly, it has been found41 that
a higher washout rate occurs in nonischemic than in ische-
mic patients. It may explain possible mechanisms involved
in differences in peak HR that we found.
Table 4. Comparison of Exercise Parameters and Left Ventricle Ejection Fraction (LVEF) Between Ischemic and Nonischemic
Patients Among Age Groups
Parameter 30e39 y 40e49 y 50e59 y 60e69 y
n 46 97 85 34
HRmax
Ischemic 140.4 6 25.0 135.0 6 22.2 123.7 6 21.8y 124 6 22.5
Nonischemic 125.0 6 25.0* 126.0 6 22.9* 120.1 6 27.0 130 6 28.0
Reserve HR
Ischemic 56.4 6 16.1 53.8 6 19.9 45.4 6 20.7 50.7 6 15.2
Nonischemic 46.8 6 24.5 49.8 6 22.1 46.7 6 21.9 48.8 6 17.8
HRrest
Ischemic 84.0 6 18.4 84.4 6 14.6 78.3 6 15.8 74.2 6 18.1
Nonischemic 78.2 6 12.4 76.2 6 11.9 73.4 6 15.7 76.2 6 16.9
Peak VO2
Ischemic 17.5 6 4.2 17.5 6 5.5 17.1 6 4.4 13.7 6 3.9z
Nonischemic 17.4 6 5.5 16.7 6 5.1 16.5 6 4.5 15.6 6 4.4
VE-VCO2 slope
Ischemic 31.8 6 15.1 31.0 6 6.7 34.1 6 7.4 35.4 6 9.3
Nonischemic 35.7 6 12.7 36.6 6 9.1* 36.6 6 10.5 34.1 6 9.4
LVEF
Ischemic 30.7 6 7.5 34.3 6 9.9 28.4 6 9.1z 28.5 6 10.1
Nonischemic 29.4 6 7.1 28.8 6 8.4* 28.7 6 9.0 27.0 6 7.4
HR, heart rate; HRmax, maximum heart rate; HRrest, resting heart rate; VO2, oxygen uptake; LVEF, left ventricle ejection fraction.
*P ! .05; nonischemic vs ischemic HF patients.
yP ! .05 compared with 30e39-y age group among ischemic HF patients.
zP ! .05 compared with 40e49-y age group among ischemic HF patients.
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Study Limitations
This was a retrospective study using selected patients
with HF referred for heart transplantation at a single center.
All patients underwent a single treadmill CPET to assess
aerobic capacity. Although data collection was not planned
and statistical analysis was exploratory, all of the patients
underwent testing on the same equipment and by the
same team, which eliminates the differences in data collec-
tion and conduction. The number of patients 20e29 and
$70 years old was relatively small, and there were only pa-
tients with nonischemic HF in those groups. Also, LVEF
values were lower and VE-VCO2 slope higher for nonische-
mic than for ischemic patients, especially in the 40e49-
year age group. However LVEF values and VE-VCO2 slope
may have influenced our results, they are applicable to the
population of patients referred for heart transplantation and
may result from similar pathophysiologic pathways.
We obtained HRrest with the patient in the standing posi-
tion just before starting exercise, and there was no differ-
ence in HRrest between groups. It is possible that the
absence of a difference in reserve HR arises from an in-
creased sympathetic drive secondary to preanticipatory
response.
Finally, these findings are based on treadmill testing only
and can not be extrapolated to upright cycle ergometer ex-
ercise testing.
Conclusion
This investigation found that equations to predict maxi-
mum heart rate are different between ischemic and noni-
schemic HF in patients receiving BB therapy. The cause
of HF should be considered when interpreting the heart
rate response in HF patients who undergo cardiopulmonary
exercise testing on a treadmill.
Disclosures
None.
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